Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 4/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702560 | 0.73 | ELANE (0.36) | ELANESCN4ANOS2NOS3NOS1 | |
| SCHEMBL17394816 | 0.72 | ELANE (0.35) | ELANESCN4ANOS2NOS3NOS1 | |
| Proline SCHEMBL28261914 | 0.72 | GRIN2D (0.35) | ELANEDPP4DPP8DPP9PARP1 | |
| SCHEMBL995604 | 0.68 | NOS2 (0.46) | ELANESCN4ANOS2NOS3NOS1 | |
| SCHEMBL6859669 | 0.68 | NOS2 (0.46) | ELANESCN4ANOS2NOS3NOS1 | |
| SCHEMBL146828 | 0.68 | NOS2 (0.46) | ELANESCN4ANOS2NOS3NOS1 | |
| SCHEMBL6790443 | 0.68 | HTR2C (0.38) | ELANESCN4ANOS2NOS3NOS1 | |
| SCHEMBL6802754 | 0.68 | HTR2C (0.38) | ELANESCN4ANOS2NOS3NOS1 | |
| SCHEMBL8305414 | 0.68 | HTR2C (0.38) | ELANESCN4ANOS2NOS3NOS1 | |
| SCHEMBL464808 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897917-B2 | Bioconjugation of polypeptides | THE UNIVERSITY OF YORK (GB) | 2024-02-13 | — | — | US | disclosed |
| US-20230121469-A1 | CATALYST FOR MANUFACTURING AMIDE COMPOUND, AND METHOD FOR MANUFACTURING AMIDE COMPOUND | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) | 2023-04-20 | — | — | US | disclosed |
| WO-2021149814-A1 | CATALYST FOR MANUFACTURING AMIDE COMPOUND, AND METHOD FOR MANUFACTURING AMIDE COMPOUND | 学校法人中部大学 | 2021-07-29 | — | — | WO | disclosed |
| US-20200317723-A1 | Bioconjugation of Polypeptides | THE UNIVERSITY OF YORK (GB) | 2020-10-08 | — | — | US | disclosed |
| EP-3688007-A1 | BIOCONJUGATION OF POLYPEPTIDES | The University of York (GB) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019063958-A1 | BIOCONJUGATION OF POLYPEPTIDES | THE UNIVERSITY OF YORK (GB) | 2019-04-04 | — | — | WO | disclosed |
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2008043798-A1 | A PROCESS FOR THE PREPARATION OF β-AMINO ALDEHYDES AND DERIVATIVES THEREOF. | ORGANOCLICK AB (SE) | 2008-04-17 | — | — | WO | disclosed |
| EP-1590442-A4 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | ELANE 123/4885SCN4A 660/4885NOS2 1891/4885 |
| US-11897917-B2 | Bioconjugation of polypeptides | PTMS, EPCAM, IAPP | ELANE 289/4885SCN4A 4771/4885NOS2 3390/4885 |
| US-20230121469-A1 | CATALYST FOR MANUFACTURING AMIDE COMPOUND, AND METHOD FOR MANUFACTURING AMIDE COMPOUND | NAAA, ASNS, BCAT2 | ELANE 823/4885SCN4A 2356/4885NOS2 578/4885 |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | ELANE 137/4885SCN4A 706/4885NOS2 2055/4885 |
| US-20200317723-A1 | Bioconjugation of Polypeptides | PTMS, EPCAM, IAPP | ELANE 289/4885SCN4A 4771/4885NOS2 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.